Tanja Obradovic has over 20 years of clinical research experience and 13 years of leading within major pharmaceutical companies development, regulatory, and medical strategy in Oncology across small molecules, Abs, cell and gene therapy, and major immunotherapy of PD1 inhibitor across 40+ solid tumor indications and lines.

She has fulfilled filing and approval of PD1 inhibitor in over 50 countries across regions including US, EU, Asia, and Latin America. Tanja has medical strategy leadership of Oncology immunotherapy drug treatment value and reimbursement policy including packages
for major private and public insurers and regulatory bodies such as Centers for Medicare & Medicaid Services (CMS) and National Institute for Health and Care Excellence (NICE). She also has over 10 years of experience in generation of medical evidence in support of value based pharmaceutical development and treatment guideline policy.